



Final Appraisal Recommendation

Advice No: 1813 – July 2013

Nepafenac (Nevanac[®]) 1 mg/ml eye drops, suspension

Submission by Alcon Laboratories (UK) Ltd

Recommendation of AWMSG

Nepafenac (Nevanac[®]) is recommended for use within NHS Wales for reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Additional note(s):

- Nepafenac (Nevanac[®]) was shown to be clinically effective when administered with prednisolone, compared with a prednisolone-only regimen.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1509), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Alcon Laboratories (UK) Ltd
Date of first issue	July 2013
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1813:
Nepafenac (Nevanac[®]) 1 mg/ml eye drops, suspension. July 2013.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.